| scholarly article | Q13442814 |
| P50 | author | Ralph A. DeFronzo | Q58689309 |
| Eleuterio Ferrannini | Q59193801 | ||
| Lawrence J Mandarino | Q91188766 | ||
| P2093 | author name string | Matsuda M | |
| Miyazaki Y | |||
| Glass L | |||
| Cusi K | |||
| Mahankali A | |||
| Mahankali S | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | preproinsulin | Q7240673 |
| P304 | page(s) | 710-719 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | |
| P478 | volume | 24 |
| Q44480091 | A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus |
| Q36536205 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes |
| Q38361567 | AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats |
| Q33575775 | Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues |
| Q33488336 | Actos Now for the prevention of diabetes (ACT NOW) study |
| Q42349595 | Approaches to treatment of type 2 diabetes |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q37176719 | Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance |
| Q45111558 | Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects |
| Q33797616 | Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes |
| Q37238946 | Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population |
| Q37957472 | Controversies surrounding the clinical potential of cinnamon for the management of diabetes |
| Q37207605 | Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective |
| Q34524559 | Current therapeutic algorithms for type 2 diabetes |
| Q83144839 | Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats |
| Q55425212 | Diabetes Mellitus Secondary to Cushing's Disease. |
| Q43266404 | Economic benefits of pioglitazone for treating patients with Type 2 diabetes |
| Q34219418 | Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the "adipose tissue expandability" hypothesis |
| Q42764571 | Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes |
| Q34509903 | Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes |
| Q28575457 | Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies |
| Q45340364 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial |
| Q52682174 | Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial. |
| Q41621514 | Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study |
| Q58549943 | Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression |
| Q52722693 | Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. |
| Q34599640 | Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records |
| Q44695536 | Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes |
| Q92141978 | Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study |
| Q40757945 | Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong |
| Q50993665 | Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. |
| Q44539697 | Evaluation of a mathematical model of diabetes progression against observations in the Diabetes Prevention Program |
| Q38183160 | Exercise- and resveratrol-mediated alterations in adipose tissue metabolism |
| Q44090287 | Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats |
| Q93016948 | From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research |
| Q38342990 | Gene expression profiling of potential PPARgamma target genes in mouse aorta |
| Q37957629 | Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. |
| Q36192546 | Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q47581724 | Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder |
| Q47912507 | Impaired peripheral insulin sensitivity in non-obese Japanese patients with type 2 diabetes mellitus and fatty liver. |
| Q37014815 | Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors |
| Q37577126 | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion |
| Q91841103 | Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone |
| Q33880303 | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 |
| Q35557363 | Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes |
| Q34502676 | Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure |
| Q45074002 | Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study |
| Q35641623 | Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy |
| Q35557366 | Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels |
| Q39692048 | New oral antidiabetic agents |
| Q34660659 | New solutions for type 2 diabetes mellitus: the role of pioglitazone |
| Q36762969 | Nonischemic heart failure in diabetes mellitus |
| Q38989466 | Obesogens and male fertility. |
| Q34416432 | PPAR gamma and human metabolic disease |
| Q36002095 | PPARgamma-mediated insulin sensitization: the importance of fat versus muscle |
| Q37072216 | PPARs and the kidney in metabolic syndrome |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q36374482 | Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism |
| Q36812788 | Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives |
| Q36466778 | Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1 |
| Q36903108 | Peroxisome proliferator-activated receptors: new players in the field of reproduction |
| Q44965022 | Pharmacokinetics of pioglitazone after multiple oral dose administration in horses |
| Q28484781 | Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations |
| Q37310692 | Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways |
| Q47785505 | Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. |
| Q34139048 | Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment |
| Q34781949 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials |
| Q35987456 | Pioglitazone and sulfonylureas: effectively treating type 2 diabetes |
| Q36842541 | Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content |
| Q45288350 | Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens |
| Q33344514 | Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome |
| Q35691510 | Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study |
| Q33590082 | Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus |
| Q27307174 | Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys |
| Q38725752 | Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes |
| Q33204628 | Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data |
| Q38349512 | Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes |
| Q44532772 | Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study |
| Q36972810 | Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial |
| Q50145335 | Pioglitazone: A review of analytical methods |
| Q50988205 | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. |
| Q28076530 | Practical combination therapy based on pathophysiology of type 2 diabetes |
| Q39176318 | Protective Effects of Red Guava on Inflammation and Oxidative Stress in Streptozotocin-Induced Diabetic Mice. |
| Q34856939 | Rationale for and role of thiazolidinediones in type 2 diabetes mellitus |
| Q79433533 | Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol |
| Q60462196 | Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus |
| Q37884618 | Review of approved pioglitazone combinations for type 2 diabetes |
| Q34434723 | Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol |
| Q36820604 | SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study |
| Q51490321 | Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. |
| Q44604963 | Sex differences in the pharmacokinetics of pioglitazone in rats |
| Q37065234 | Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes |
| Q36203979 | Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats |
| Q46711309 | Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes |
| Q64111538 | Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease |
| Q37304485 | The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. |
| Q28222372 | The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians? |
| Q35212543 | The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease |
| Q51311315 | The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo. |
| Q45201526 | The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes |
| Q38102596 | The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. |
| Q26782181 | The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials |
| Q36921672 | The importance of free fatty acids in the development of Type 2 diabetes. |
| Q35563453 | The management of the obese diabetic patient |
| Q26851905 | Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention |
| Q36920649 | Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. |
| Q38985320 | Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials |
| Q51485541 | Thiazolidinediones improve beta-cell function in type 2 diabetic patients. |
| Q34628604 | Thiazolidinediones in the treatment of type 2 diabetes |
| Q35162317 | Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence |
| Q42439893 | Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects |
| Q26783350 | Treatment of prediabetes |
| Q36474275 | Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial |
| Q35557355 | Type 2 diabetes, cardiovascular risk, and the link to insulin resistance |
| Q38241464 | What are the pharmacotherapy options for treating prediabetes? |
| Q45360810 | Which is the eligible patient to be treated with pioglitazone? The expert view |
| Q51496603 | [Prevention of type 2 diabetes mellitus]. |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
Search more.